Clinical and molecular-biologic features of infant acute leukemia
https://doi.org/10.17650/1818-8346-2022-17-2-23-29
Abstract
Acute leukemia (AL) in children up 1 year old is very rare disease, comprise less 5 % of all pediatric AL cases. The clinical course of infant AL is extremely aggressive with frequent extramedullar dissemination, initial hyperleukocytosis and MLL aberrations. Predominance of unfavorable clinical and laboratory features leads to unsatisfactory treatment results by modern curative protocols in children up to 1 year old: 4-year event-free survival for acute lymphoblastic leukemia is 50.9 ± 4.5 % and 3-year event-free survival for acute myeloid leukemia – 72–74 %.
Optimization of therapeutic programs for infant AL with consideration to anatomy and physiologic features of infants, inclusion of targeted drugs (blinatumomab), epigenetic and cell technologies is actual and not resolved problem in modern pediatric oncology-hematology.
About the Authors
Y. S. Korkina
Russian Medical Academy of Continuing Postgraduate Education, Ministry of Health of Russia
Russian Federation
Russian Federation
125993, Moscow, 2/1 Barrikadnaya St., Build. 1
T. T. Valiev
Russian Medical Academy of Continuing Postgraduate Education, Ministry of Health of Russia; Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
125993, Moscow, 2/1 Barrikadnaya St., Build. 1
115478, Moscow, Kashirskoe Shosse, 24
S. R. Varfolomeeva
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
115478, Moscow, Kashirskoe Shosse, 24
References
1. Wertheim G. Infant acute leukemia. Clin Lab Med 2021;41(3):541–50. DOI:10.1016/j.cll.2021.04.002.
2. Brethon B., Cavé H., Fahd M. et al. Les leucémies aiguës de l’enfant de moins d’un an: des maladies rares, encore un défi [Infant acute leukemia (in French)]. Bull Cancer 2016;103(3):299–311. DOI:10.1016/j.bulcan.2015.11.009.
3. Gabitova N.H., Zhdanova S.I., Cherezova I.N. et al. A case of congenital lymphoblastic leukemia in a newborn baby. Rossiyskiy vestnik perinatologii i pediatrii = Russian Bulletin of Perinatology and Pediatrics 2020;65(5):204–8. (In Russ.). DOI:10.21508/1027-4065-2020-65-5204-208.
4. Bogadel’nikov I.V., Usova S.V., Dyabina T.A. et al. Case of acute leukemia in infant. Zdorov’e rebenka = Child Health 2013;2(45): 121–6. (In Russ.).
5. Nechaev V.N., Chernenkov Yu.V., Mishinа O.A. et al. Congenital megakaryoblastic leukemia: a clinical case. Saratovskiy nauchnomeditsintskiy zhurnal = Saratov Journal of Medical Scientific Research 2019;15(1):34–40. (In Russ.).
6. Emerenciano M., Koifman S., Pombo-deOliveira M.S. Acute leukemia in early childhood. Braz J Med Biol Res 2007;40(6):749–60. DOI:10.1590/s0100-879x2007000600002.
7. Valentine M.C., Linabery A.M., Chasnoff S. et al. Excess congenital nonsynonymous variation in leukemiaassociated genes in MLL-infant leukemia: a Children’s Oncology Group report. Leukemia 2014;28(6):1235–41. DOI:10.1038/leu.2013.367.
8. Sidorenko L.V. Long-term effects of pediatric cancer therapy, an individual approach in the development of personalized programs for medical, psychological and social rehabilitation of patients cured of cancer in childhood. Methodical recommendations for dispensary observation. Orenburg, 2020. (In Russ.).
9. Artemova N.S., Cvirenko S.N., Pokhilko V.I. et al. A clinical case of neonatal acute lymphoblastic leukemia. Zdorov’e rebenka = Child Health 2019;14(5):317–22. (In Russ.). DOI:10.22141/22240551.14.5.2019.177408.
10. Gale K.B., Ford A.M., Repp R. et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997;94(25):13950–4. DOI:10.1073/pnas.94.25.13950.
11. Brown P., Pieters R., Biondi A. How I treat infant leukemia. Blood 2019;133(3):205–14. DOI:10.1182/blood-2018-04-785980.
12. Schäfer D., Olsen M., Lähnemann D. et al. Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood 2018;131(7):821–6. DOI:10.1182/blood-2017-09-808402.
13. Zuna J., Madzo J., Krejci O. et al. ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia. Blood 2011;117(1):368–71. DOI:10.1182/blood-2010-09-309070.
14. Hein D., Borkhardt A., Fischer U. Insights into the prenatal origin of childhood acute lymphoblastic leukemia. Cancer Metastasis Rev 2020;39(1):161–71. DOI:10.1007/s10555-019-09841-1.
15. Tomizawa D., Miyamura T., Imamura T. et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood 2020;136(16):1813–23. DOI:10.1182/blood.2019004741.
16. Mikheeva N.G., Grigoryeva N.N., Kletskiy S.K. et al. A case of acute megakaryoblastic myeloid leukemia in the fetus. Prenatal’naya diagnostika = Prenatal Diagnostics 2013;12(4):335–9. (In Russ.).
17. Zhang H., Cheng J., Li Z., Xi Y. Identification of hub genes and molecular mechanisms in infant acute lymphoblastic leukemia with MLL gene rearrangement. Peer J 2019;7:e7628. DOI:10.7717/peerj.7628.
18. Bahoush G., Vafapour M., Kariminejad R. Detection of new translocation in infant twins with concordant ALL and discordant outcome. Pediatr Rep 2020;13(1):9–14. DOI:10.3390/pediatric13010002.
19. Sanjuan-Pla A., Bueno C., Prieto C. et al. Revisiting the biology of infant t(4;11)/ MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood 2015;126(25):2676–85. DOI:10.1182/blood-2015-09-667378.
20. Feng Z., Yao Y., Zhou C. et al. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol 2016;9:24. DOI:10.1186/s13045-016-0252-7.
21. Tsaur G.A. The structure of chimeric genes with the participation of the MLL gene in acute leukemia in children of the first year of life. Onkopediatriya = Oncopediatrics 2014;3:81. (In Russ.).
22. Tsaur G.A., Meye C.R., Popov A.M. et al. Study of the structure of chimeric genes with the participation of the MLL gene in acute leukemia in children of the first year of life. Vestnik gematologii = Hematology Bulletin 2014;10(2):96–7. (In Russ.).
23. Tsaur G.A., Popov A.M., Nasedkina T.V. et al. Monitoring of chimeric transcripts with the participation of the MLL gene to assess the prognostic value of minimal residual disease in acute lymphoblastic leukemia in infants under the MLL-baby protocol. Gematologiya i transfuziologiya = Hematology and Transfusiology 2012;57(3):27. (In Russ.).
24. Tsaur G.A., Popov A.M., Nasedkina T.V. et al. Comparison of bone marrow and peripheral blood for monitoring minimal residual disease in acute lymphoblastic leukemia in infants under the MLL-Baby protocol. Gematologiya i transfuziologiya = Hematology and Transfusiology 2014;59(1):70. (In Russ.).
25. Kosasih H.J., Davidson N.M., Bjelosevic S. et al. MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia. Blood Adv 2020;4(19):4918–23. DOI:10.1182/bloodadvances.2020002708.
26. Paina O.V., Semenova E.V., Markova I.V. et al. Modern views on the treatment of acute leukemia in children under 1 year. Russian Journal of Rossiyskiy zhurnal detskoy gematologii i onkologii = Pediatric Hematology аnd Oncology 2019;6(2):11–9. (In Russ.). DOI:10.21682/2311-1267-2019-6-2-11-19.
27. Vlasova A.A., Vakhonina L.V., Vyatkin I.N. et al. Experience of hematopoietic stem cell transplantation in high-risk infantile leukemia. Rossiyskiy zhurnal detskoy gematologii i onkologii = Pediatric Hematology аnd Oncology 2019;6(1):82–3. (In Russ.).
28. De Rooij J.D., Masetti R., Van den Heuvel-Eibrink M.M. et al. Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood 2016;127(26):3424–30. DOI:10.1182/blood-2016-01-695551.
29. Masetti R., Bertuccio S.N., Pession A. et al. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol 2019;184(3):337–47. DOI:10.1111/bjh.15725.
30. Dreyer Z.E., Hilden J.M., Jones T.L. et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer 2015;62(3):419–26. DOI:10.1002/pbc.25322.
31. Aleskerova G.A., Shervashidze M.A., Popa A.V. et al. Results of the treatment of acute lymphoblastic leukemia in children according to the ALL IC-BFM 2002 protocol. Onkopediatriya = Oncopediatrics 2016;3(4):302–8. (In Russ.).
32. Woods W.G., Neudorf S., Gold S. et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97(1):56–62. DOI:10.1182/blood.v97.1.56.
Review
For citations:
Korkina Y.S., Valiev T.T., Varfolomeeva S.R. Clinical and molecular-biologic features of infant acute leukemia. Oncohematology. 2022;17(2):23-29. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-2-23-29
Views:
9418
Email this article 